ITPD910013A1 - Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli. - Google Patents

Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli.

Info

Publication number
ITPD910013A1
ITPD910013A1 IT000013A ITPD910013A ITPD910013A1 IT PD910013 A1 ITPD910013 A1 IT PD910013A1 IT 000013 A IT000013 A IT 000013A IT PD910013 A ITPD910013 A IT PD910013A IT PD910013 A1 ITPD910013 A1 IT PD910013A1
Authority
IT
Italy
Prior art keywords
neuronotroficociliar
cntf
purification
synthesis
factor
Prior art date
Application number
IT000013A
Other languages
English (en)
Inventor
Tiziana Bisogno
Lanfranco Callegaro
Alessandro Negro
Original Assignee
Fidia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Spa filed Critical Fidia Spa
Priority to ITPD910013A priority Critical patent/IT1247150B/it
Publication of ITPD910013A0 publication Critical patent/ITPD910013A0/it
Priority to PCT/EP1992/000122 priority patent/WO1992013072A2/en
Priority to AU11656/92A priority patent/AU1165692A/en
Priority to EP92902811A priority patent/EP0566630A1/en
Publication of ITPD910013A1 publication Critical patent/ITPD910013A1/it
Application granted granted Critical
Publication of IT1247150B publication Critical patent/IT1247150B/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ITPD910013A 1991-01-21 1991-01-21 Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli. IT1247150B (it)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ITPD910013A IT1247150B (it) 1991-01-21 1991-01-21 Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli.
PCT/EP1992/000122 WO1992013072A2 (en) 1991-01-21 1992-01-21 Process for the synthesis and purification of human ciliary neuronotrophic factor (cntf) from escherichia coli
AU11656/92A AU1165692A (en) 1991-01-21 1992-01-21 Process for the synthesis and purification of human ciliary neuronotrophic factor (cntf) from escherichia coli
EP92902811A EP0566630A1 (en) 1991-01-21 1992-01-21 Process for the synthesis and purification of human ciliary neuronotrophic factor (cntf) from escherichia coli

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITPD910013A IT1247150B (it) 1991-01-21 1991-01-21 Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli.

Publications (3)

Publication Number Publication Date
ITPD910013A0 ITPD910013A0 (it) 1991-01-21
ITPD910013A1 true ITPD910013A1 (it) 1992-07-21
IT1247150B IT1247150B (it) 1994-12-12

Family

ID=11389421

Family Applications (1)

Application Number Title Priority Date Filing Date
ITPD910013A IT1247150B (it) 1991-01-21 1991-01-21 Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli.

Country Status (4)

Country Link
EP (1) EP0566630A1 (it)
AU (1) AU1165692A (it)
IT (1) IT1247150B (it)
WO (1) WO1992013072A2 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98304A (en) * 1990-06-01 2008-08-07 Regeneron Pharma The ciliary neurotrophic factor receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141856A (en) * 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
DE3900198A1 (de) * 1989-01-05 1990-07-12 Merck Patent Gmbh Topisch anwendbare pharmazeutische zubereitung
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
HUT62033A (en) * 1990-03-14 1993-03-29 Fidia Spa Process for producing human ciliary body neuronotropic factor

Also Published As

Publication number Publication date
WO1992013072A3 (en) 1992-09-17
ITPD910013A0 (it) 1991-01-21
EP0566630A1 (en) 1993-10-27
IT1247150B (it) 1994-12-12
AU1165692A (en) 1992-08-27
WO1992013072A2 (en) 1992-08-06

Similar Documents

Publication Publication Date Title
NO941383D0 (no) Stabilisering av humant interferon
GB9115276D0 (en) Skin treatment system
MX9205981A (es) Administracion transdermica de melatonina.
CA2163361A1 (en) Therapeutic substituted guanidines
DK19893D0 (da) Praeparat til nasal behandling
FI933193A7 (fi) Kasvainsairauden hoito interleukiini-10:llä
AU1197992A (en) The use of loperamide and related compounds for treatment of respiratory disease symptoms
ITBO920277A1 (it) Endoprotesi per osteosintesi del femore prossimale
NO304384B1 (no) Al-Sr-Si-B-forlegering, fremgangsmÕte for dens fremstilling og anvendelse av forlegeringen
GB9120867D0 (en) The treatment of meat
ITBO910011V0 (it) Dispositivo per ridurre le fratture trocanteriche, condiliche e del collo del femore
ITMI920807A1 (it) Procedimento per la preparazione di ginkgolide b da ginkgolide c
AU2807492A (en) Use of misoprostol for the treatment of allergy
ITPD910013A1 (it) Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli.
NO924290D0 (no) Azabenzimidazoler for behandling av astma, artritt og lignende lidelser
AU1898792A (en) Treatment or therapeutic booth for energetic, cosmetic and medical purposes
NO970185D0 (no) Anvendelse av (S)-adenosyl-L-metionin (SAMe) og dets fysiologisk kompatible salter for behandling av reperfusjonsskade utlöst av temporær-fokal-ischemi
ITMI913466A0 (it) Procedimento per la depurazione dell'1.1.1-trifluoro-2-fluoroetano e dell'1.1.1-trifuoro-2,2-diocloroetano
EP0552289A4 (en) Prevention or treatment of sunburn using the s(+) isomer of ketoprofen
FR2681320B1 (fr) Derives de n-(4,7dimethoxyindan-2-yl)-1-(phenylcarbonyl)-n-propyl-piperidine-4-methanamine, leur preparation et leur application en therapeutique.
ZA923125B (en) Treatment of mastitis
ITPD910207A1 (it) Processo per la sintesi e la purificazione di forme troncate del fattore neuronotrofico ciliare umano
IT9019699A0 (it) Procedimento di purificazione del b-interferone umano ricombinante
IT1248835B (it) Procedimento e apparecchiatura per la preparazione di nylon-6 da e-caprolattame con trattamento con ultrasuoni
ITRM930259A0 (it) Procedimento per la purificazione e stabilizzazione di perfluoropolieteri.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19960126